免疫蛋白診斷檢測市場－全球產業規模、佔有率、趨勢、機會及預測（依檢測方法、技術、應用、通路、最終用途、地區及競爭格局分類），2021-2031年

全球免疫蛋白診斷測試市場預計將從 2025 年的 108.8 億美元成長到 2031 年的 169.3 億美元，複合年成長率為 7.65%。

此診斷領域涉及對特定蛋白質（例如免疫球蛋白和細胞激素）進行定性和定量檢測，以識別從自體免疫疾病到感染疾病等多種健康問題。推動該市場成長的關鍵因素是慢性病在全球日益普遍，以及早期醫療介入對促進患者復原的重要性日益凸顯。此外，人口老化也顯著推動了對精準診斷工具的需求，因為老年人通常需要更頻繁、更深入的臨床監測。

儘管市場環境有利，但實施自動化診斷系統的高昂成本仍然是市場准入的一大障礙，尤其是在醫療資源有限的地區。美國癌症協會預測，到2024年，美國將新增約2,001,140例癌症病例，顯示需要進行此類檢測的疾病負擔日益加重。如此高的發病率預測凸顯了建立強大的診斷檢測基礎設施以支持及時有效的患者照護策略的必要性。

市場促進因素

慢性病和感染疾病率的上升是全球免疫蛋白診斷檢測市場的主要驅動力。這種成長催生了對能夠檢測特定生物標記（例如細胞激素和免疫球蛋白）的精準免疫分析的需求，這些生物標記對於確診和追蹤疾病進展至關重要。隨著傳染性病原體的變異和慢性病的日益普遍，醫療系統高度依賴這些工具來進行有效的患者管理和早期檢測。世界衛生組織（世衛組織）在其2024年4月發布的《2024年全球肝炎報告》中強調了感染疾病的嚴重性，報告指出，2022年病毒性肝炎相關死亡人數預計將達到130萬，這凸顯了建立強大的檢測能力以應對這一全球健康風險的緊迫性。

此外，免疫檢測平台的技術進步和就地檢驗的廣泛應用，透過提高檢測的便利性和速度，正在加速市場成長。現代實驗室正在部署高通量分析儀，以處理與各種慢性疾病相關的大量檢測。例如，美國心臟協會報告稱，到2024年，約有48.6%的美國成年人將患有某種形式的心血管疾病，這使得蛋白質生物標記對於該疾病的風險評估至關重要。因此，診斷設備製造商獲得了可觀的收入。根據丹納赫公司於2024年2月發布的2023年度報告，該公司診斷設備部門預計將創造96億美元的收入，從而確保其診斷能力的擴充性，以滿足全球不斷成長的臨床需求。

市場挑戰

全球免疫蛋白診斷檢測市場成長的主要障礙之一是實施自動化診斷系統的高成本。先進的免疫蛋白分析儀需要大量的初始資本投入，不僅包括設備購置，還包括安裝、校準和人員培訓費用。這種資本投入構成了進入門檻，尤其對於預算有限的小規模實驗室和醫療機構而言更是如此。因此，許多機構推遲採用最新的診斷工具，被迫繼續使用速度和效率都遠不及現代自動化平台的舊系統。

近期醫院支出方面的產業統計數據凸顯了推遲關鍵技術升級的趨勢。根據美國醫院協會2024年的報告，由於醫療機構為應對不斷上漲的營運成本而推遲採購決策，醫療基礎設施和設備資本投資的平均使用年限同比成長了7.1%。這種財政謹慎的做法使得醫療機構難以資金籌措資金用於基礎設施更新，限制了高通量免疫蛋白檢測解決方案的普及，並直接阻礙了市場擴張。

市場趨勢

將人工智慧 (AI) 和機器學習融入診斷工作流程，顯著提升了營運效率和分析準確性，從而正在深刻改變全球免疫蛋白診斷檢測市場。檢查室擴大使用 AI 演算法來分析複雜的蛋白質模式，並實現數位病理切片評估的自動化，從而最大限度地減少人為錯誤，並更快地提供結果。這種技術整合使得處理精準醫療所需的大型資料整合為可能，尤其是在免疫學和腫瘤學領域。羅氏公司在 2024 年 9 月發布的題為「羅氏推進 AI 驅動的癌症診斷」的新聞稿中，就反映了這一趨勢。該公司在新聞稿中宣布，已在其數位病理生態系統中整合了 20 多種新的 AI 演算法，以幫助臨床醫生識別特定的腫瘤分化等級和生物標記。

此外，直接面對消費者 (DTC) 和居家檢體採集模式的成長，標誌著醫療保健服務正朝著去中心化、以患者為中心的方向發生重要轉變。主要市場參與者正在迅速擴展其產品和服務，允許個人在線上購買某些健康和免疫蛋白檢測，從而繞過傳統的臨床中介機構，促進主動健康管理。這種診斷的普及化正在推動在傳統醫院環境之外進行的檢測數量顯著增加。例如，Quest Diagnostics 在 2024 年 6 月發布的 2023 年企業責任報告中揭露，其面向消費者的平台上提供的檢測數量幾乎加倍，降低了患者獲取快速便捷診斷資訊的門檻。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球免疫蛋白診斷檢測市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依檢測類型（補體系統蛋白診斷試驗、遊離輕鏈診斷試驗、肝珠蛋白診斷試驗、免疫球蛋白診斷試驗、前白蛋白診斷試驗、C反應蛋白（CRP）診斷試驗）
  • 依技術（免疫測量、酵素免疫分析法測定法、化學發光測定、螢光、免疫比濁法、免疫蛋白電泳）
  • 依應用領域（傳染病檢查、腫瘤檢測、內分泌檢測、毒性檢測、過敏檢測、自體免疫疾病檢測）
  • 按分銷管道（直接競標和零售）
  • 透過申請（醫院/診所、診斷檢查室等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北美免疫蛋白診斷檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲免疫蛋白診斷檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章 亞太地區免疫蛋白質診斷檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章 中東和非洲免疫蛋白診斷檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美洲免疫蛋白診斷檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章：全球免疫蛋白診斷檢測市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Agilent Technologies, Inc.
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• PerkinElmer, Inc.
• Bio-Rad Laboratories, Inc.
• Aurora Biomed Inc.
• Tecan Trading AG
• Promega Corporation
• Charles River Laboratories International, Inc.
• Creative Biolabs, Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Immunoprotein Diagnostic Testing Market is projected to expand from USD 10.88 Billion in 2025 to USD 16.93 Billion by 2031, reflecting a CAGR of 7.65%. This diagnostic field involves the qualitative and quantitative examination of specific proteins, including immunoglobulins and cytokines, to identify a spectrum of health issues ranging from autoimmune diseases to infections. Key drivers fueling this market growth include the increasing global prevalence of chronic diseases and the vital need for early medical intervention to enhance patient recovery. Additionally, the aging global population significantly bolsters the demand for precise diagnostic measures, as this demographic typically necessitates frequent and thorough clinical monitoring.

Despite these favorable growth conditions, the substantial costs required to implement automated diagnostic systems create a significant barrier to market entry, particularly in regions with restricted healthcare funds. To demonstrate the rising disease burden that mandates these tests, the American Cancer Society projected in 2024 that approximately 2,001,140 new cancer cases would occur in the United States. This high volume of anticipated disease incidence underscores the critical necessity for a strong diagnostic testing infrastructure to support timely and effective patient care strategies.

Market Driver

The rising incidence of chronic and infectious diseases acts as a major driver for the Global Immunoprotein Diagnostic Testing Market. This increase creates a demand for accurate immunological assays capable of detecting specific biomarkers, such as cytokines and immunoglobulins, which are crucial for confirming diagnoses and tracking disease development. As infectious agents mutate and chronic illnesses become more common, healthcare frameworks depend heavily on these tools for efficient patient management and early detection. Highlighting the gravity of infectious diseases, the World Health Organization reported in its 'Global Hepatitis Report 2024' from April 2024 that viral hepatitis-related deaths climbed to an estimated 1.3 million in 2022, emphasizing the urgent need for strong testing frameworks to handle global health risks.

Furthermore, technological progress in immunoassay platforms and the increasing use of point-of-care testing are accelerating market growth by enhancing accessibility and speed. Modern laboratories are adopting high-throughput analyzers to manage the large testing volumes associated with widespread chronic conditions. For instance, the American Heart Association reported in 2024 that roughly 48.6% of adults in the United States suffered from some form of cardiovascular disease, a condition that relies heavily on protein biomarkers for risk assessment. Consequently, diagnostic manufacturers are seeing significant financial returns; Danaher Corporation's '2023 Annual Report' from February 2024 noted that its Diagnostics segment yielded revenues of $9.6 billion, ensuring that diagnostic capacities remain scalable to meet growing global clinical needs.

Market Challenge

A major obstacle to the growth of the Global Immunoprotein Diagnostic Testing Market is the high cost associated with implementing automated diagnostic systems. Advanced immunoprotein analyzers demand significant upfront capital investment, covering not just the purchase of equipment but also costs for installation, calibration, and staff training. This financial requirement establishes a difficult barrier to entry, especially for smaller laboratories and healthcare facilities with limited budgets. As a result, many organizations are compelled to delay acquiring modern diagnostic tools, choosing instead to rely on older systems that may lack the speed or efficiency of contemporary automated platforms.

The tendency to delay essential technological upgrades is highlighted by recent industry statistics concerning hospital expenditures. According to the 'American Hospital Association' in '2024', the average age of capital investments for medical infrastructure and equipment rose by 7.1% over the previous year as facilities postponed purchasing decisions to cope with rising operating costs. This financial caution directly impedes market expansion, as the inability of healthcare providers to fund updated infrastructure limits the adoption of high-throughput immunoprotein testing solutions.

Market Trends

The incorporation of Artificial Intelligence and Machine Learning into diagnostic workflows is significantly transforming the Global Immunoprotein Diagnostic Testing Market by improving operational efficiency and analytical accuracy. Laboratories are increasingly utilizing AI algorithms to analyze complex protein patterns and automate the assessment of digital pathology slides, thereby minimizing human error and accelerating the delivery of results. This convergence of technologies facilitates the processing of massive datasets necessary for precision medicine, especially within immunology and oncology. Confirming this trend, Roche announced in a September 2024 press release titled 'Roche advances AI-driven cancer diagnostics' that it had integrated over 20 new AI algorithms into its digital pathology ecosystem to assist clinicians in identifying specific tumor gradings and biomarkers.

Additionally, the growth of Direct-to-Consumer and At-Home Sample Collection Models marks a significant shift toward decentralized, patient-focused healthcare access. Leading market players are rapidly expanding their service offerings to enable individuals to purchase specific wellness and immunoprotein tests online, sidestepping traditional clinical intermediaries and encouraging proactive health management. This democratization of diagnostics is fueling substantial volume increases outside conventional hospital environments. Demonstrating this rapid uptake, Quest Diagnostics revealed in its '2023 Corporate Responsibility Report' from June 2024 that the company had nearly doubled the number of tests offered on its consumer-facing platform, thereby lowering entry barriers for patients looking for immediate and convenient diagnostic insights.

Key Market Players

• Agilent Technologies, Inc.
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• PerkinElmer, Inc.
• Bio-Rad Laboratories, Inc.
• Aurora Biomed Inc.
• Tecan Trading AG
• Promega Corporation
• Charles River Laboratories International, Inc.
• Creative Biolabs, Inc

Report Scope

In this report, the Global Immunoprotein Diagnostic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Immunoprotein Diagnostic Testing Market, By Test

• Complement System Proteins Diagnostic Tests
• Free Light Chain Diagnostic Tests
• Haptoglobin Diagnostic Tests
• Immunoglobulin Diagnostic Tests
• Prealbumin Diagnostic Tests
• C-Reactive Protein (CRP) Diagnostic Tests

Immunoprotein Diagnostic Testing Market, By Technology

• Radioimmunoassay
• Enzyme Based Immunoassay
• Chemiluminescence Assay
• Immunofluorescence Assay
• Immunoturbidity Assay
• Immunoprotein Electrophoresis

Immunoprotein Diagnostic Testing Market, By Application

• Infectious Disease Testing
• Oncology Testing
• Endocrine Testing
• Toxicology Testing
• Allergy Testing
• Autoimmune Disease Testing

Immunoprotein Diagnostic Testing Market, By Distribution Channel

• Direct Tender
• Retail Sales

Immunoprotein Diagnostic Testing Market, By End Use

• Hospitals & Clinics
• Diagnostic Laboratories
• Others

Immunoprotein Diagnostic Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Immunoprotein Diagnostic Testing Market.

Available Customizations:

Global Immunoprotein Diagnostic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Immunoprotein Diagnostic Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test (Complement System Proteins Diagnostic Tests, Free Light Chain Diagnostic Tests, Haptoglobin Diagnostic Tests, Immunoglobulin Diagnostic Tests, Prealbumin Diagnostic Tests, and C-Reactive Protein (CRP) Diagnostic Tests)
  • 5.2.2. By Technology (Radioimmunoassay, Enzyme Based Immunoassay, Chemiluminescence Assay, Immunofluorescence Assay, Immunoturbidity Assay, and Immunoprotein Electrophoresis)
  • 5.2.3. By Application (Infectious Disease Testing, Oncology Testing, Endocrine Testing, Toxicology Testing, Allergy Testing, and Autoimmune Disease Testing)
  • 5.2.4. By Distribution Channel (Direct Tender and Retail Sales)
  • 5.2.5. By End Use (Hospitals & Clinics, Diagnostic Laboratories and Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Immunoprotein Diagnostic Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By Distribution Channel
  • 6.2.5. By End Use
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Immunoprotein Diagnostic Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By Distribution Channel
      • 6.3.1.2.5. By End Use
  • 6.3.2. Canada Immunoprotein Diagnostic Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By Distribution Channel
      • 6.3.2.2.5. By End Use
  • 6.3.3. Mexico Immunoprotein Diagnostic Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By Distribution Channel
      • 6.3.3.2.5. By End Use

7. Europe Immunoprotein Diagnostic Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By Distribution Channel
  • 7.2.5. By End Use
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Immunoprotein Diagnostic Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By Distribution Channel
      • 7.3.1.2.5. By End Use
  • 7.3.2. France Immunoprotein Diagnostic Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By Distribution Channel
      • 7.3.2.2.5. By End Use
  • 7.3.3. United Kingdom Immunoprotein Diagnostic Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By Distribution Channel
      • 7.3.3.2.5. By End Use
  • 7.3.4. Italy Immunoprotein Diagnostic Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By Distribution Channel
      • 7.3.4.2.5. By End Use
  • 7.3.5. Spain Immunoprotein Diagnostic Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By Distribution Channel
      • 7.3.5.2.5. By End Use

8. Asia Pacific Immunoprotein Diagnostic Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By Distribution Channel
  • 8.2.5. By End Use
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Immunoprotein Diagnostic Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By Distribution Channel
      • 8.3.1.2.5. By End Use
  • 8.3.2. India Immunoprotein Diagnostic Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By Distribution Channel
      • 8.3.2.2.5. By End Use
  • 8.3.3. Japan Immunoprotein Diagnostic Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By Distribution Channel
      • 8.3.3.2.5. By End Use
  • 8.3.4. South Korea Immunoprotein Diagnostic Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By Distribution Channel
      • 8.3.4.2.5. By End Use
  • 8.3.5. Australia Immunoprotein Diagnostic Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By Distribution Channel
      • 8.3.5.2.5. By End Use

9. Middle East & Africa Immunoprotein Diagnostic Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By Distribution Channel
  • 9.2.5. By End Use
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Immunoprotein Diagnostic Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By Distribution Channel
      • 9.3.1.2.5. By End Use
  • 9.3.2. UAE Immunoprotein Diagnostic Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By Distribution Channel
      • 9.3.2.2.5. By End Use
  • 9.3.3. South Africa Immunoprotein Diagnostic Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By Distribution Channel
      • 9.3.3.2.5. By End Use

10. South America Immunoprotein Diagnostic Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By Distribution Channel
  • 10.2.5. By End Use
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Immunoprotein Diagnostic Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By Distribution Channel
      • 10.3.1.2.5. By End Use
  • 10.3.2. Colombia Immunoprotein Diagnostic Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By Distribution Channel
      • 10.3.2.2.5. By End Use
  • 10.3.3. Argentina Immunoprotein Diagnostic Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By Distribution Channel
      • 10.3.3.2.5. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Immunoprotein Diagnostic Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Agilent Technologies, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Danaher Corporation
• 15.3. Thermo Fisher Scientific Inc.
• 15.4. PerkinElmer, Inc.
• 15.5. Bio-Rad Laboratories, Inc.
• 15.6. Aurora Biomed Inc.
• 15.7. Tecan Trading AG
• 15.8. Promega Corporation
• 15.9. Charles River Laboratories International, Inc.
• 15.10. Creative Biolabs, Inc

16. Strategic Recommendations

17. About Us & Disclaimer